Deficiency of TDAG51 Protects Against Atherosclerosis by Modulating Apoptosis, Cholesterol Efflux, and Peroxiredoxin‐1 Expression
Authors: Sárka Lhoták
Gazi S Hossain
Jeffrey G Dickhout
Damu Tang
Ji Zhou
Imtisal Al-Bondokji
Bernardo Trigatti
Edward G Lynn
Mary J Malloy
Yonghong Li
Kenneth N Maclean
John Capone
Richard C Austin
Jaerang Rho
John P Kane
Dov Shiffman
Clive R Pullinger
Christopher A McCulloch
Journal: Journal of the American Heart Association (2013)
Discipline: CLINICAL MEDICINE
Keywords: apoptosis; arteriosclerosis; atherosclerosis; cardiovascular diseases.
Affiliations: Division of Nephrology, Department of Medicine, McMaster University and St. Joseph's Healthcare Hamilton, Ontario, Canada., Division of Nephrology, Department of Medicine, McMaster University and St. Joseph's Healthcare Hamilton, Ontario, Canada, Department of Pediatrics, School of Medicine University of Colorado Health Sciences Center, Aurora, CO, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada, Office of the Vice‐President (Research), Western University, London, Ontario, Canada, Department of Microbiology and Molecular Biology and GRAST, Gung‐dong, Yuseong‐gu, Daejeon, Korea, Matrix Dynamics Group, University of Toronto, Toronto, Ontario, Canada, Cardiovascular Research Institute, University of California, San Francisco, CA, Celera, 1401 Harbor Bay Parkway, Alameda, CA

Abstract:  Background: Apoptosis caused by endoplasmic reticulum (ER) stress contributes to atherothrombosis, the underlying cause of cardiovascular disease (CVD). T-cell death-associated gene 51 (TDAG51), a member of the pleckstrin homology-like domain gene family, is induced by ER stress, causes apoptosis when overexpressed, and is present in lesion-resident macrophages and endothelial cells. Methods and results: To study the role of TDAG51 in atherosclerosis, male mice deficient in TDAG51 and apolipoprotein E (TDAG51(-/-)/ApoE(-/-)) were generated and showed reduced atherosclerotic lesion growth (56 ± 5% reduction at 40 weeks, relative to ApoE(-/-) controls, P&lt;0.005) and necrosis (41 ± 4% versus 63 ± 8% lesion area in TDAG51(-/-)/ApoE(-/-) and ApoE(-/-), respectively; P&lt;0.05) without changes in plasma levels of lipids, glucose, and inflammatory cytokines. TDAG51 deficiency caused several phenotypic changes in macrophages and endothelial cells that increase cytoprotection against oxidative and ER stress, enhance PPARγ-dependent reverse cholesterol transport, and upregulate peroxiredoxin-1 (Prdx-1), an antioxidant enzyme with antiatherogenic properties (1.8 ± 0.1-fold increase in Prdx-1 protein expression, relative to control macrophages; P&lt;0.005). Two independent case-control studies found that a genetic variant in the human TDAG51 gene region (rs2367446) is associated with CVD (OR, 1.15; 95% CI, 1.07 to 1.24; P=0.0003). Conclusions: These findings provide evidence that TDAG51 affects specific cellular pathways known to reduce atherogenesis, suggesting that modulation of TDAG51 expression or its activity may have therapeutic benefit for the treatment of CVD. 

Retracted: No

PubPeer comments:
 An image and figure 3 and figure 6 appear to be repeated. Note: first author may now be at Northwestern University, however I was unable to find that email address. *** ![file] *** ![file] ,